CRISPR_Cas9_screens_for_drug_resistance_in_AML_cell_lines-sc-3362
CRISPR_Cas9_screens_for_drug_resistance_in_AML_cell_lines
Acute myeloid leukaemia (AML) continues to have a very high mortality and its treatment has not changed for more than 20 years. Here, we propose to apply genomic-wide screens to directly identify therapeutic vulnerabilities of AML using AML cells lines with pre-defined somatic mutations. Our studies will be based on genome-wide CRISPR/CAs9 gRNA screens and will be used to identify drivers of drug resistance to standard chemotherapies.  This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
Acute myeloid leukaemia (AML) continues to have a very high mortality and its treatment has not changed for more than 20 years. Here, we propose to apply genomic-wide screens to directly identify therapeutic vulnerabilities of AML using AML cells lines with pre-defined somatic mutations. Our studies will be based on genome-wide CRISPR/CAs9 gRNA screens and will be used to identify drivers of drug resistance to standard chemotherapies.